Bone Biologics CORP DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
Bone Biologics Corporation announces its 2026 Annual Meeting of Stockholders to be held on August 11, 2026, to elect directors, approve executive compensation, and ratify auditor appointment.
NASDAQ
DEF: Bone Biologics Seeks Stockholder Approval for Reverse Stock Split and Amended Equity Incentive Plan
Bone Biologics is asking stockholders to approve a reverse stock split and an amendment to its equity incentive plan at the upcoming annual meeting.
NASDAQ
Bone Biologics Corporation has filed a definitive proxy statement with the SEC.
NASDAQ
Bone Biologics Corporation will hold its 2024 Annual Meeting of Stockholders on September 17, 2024, to elect directors, approve executive compensation, and ratify the appointment of its independent accounting firm.